Skip to main content

Providers
Life Sciences
Resources
Project ECHO® Learning Series

Evolving Role of Bispecific Antibodies as Cancer Therapy

Join ACCC, Physicians' Education Resource (PER), and Pharmacy Times Continuing Education (PTCE) for a five-part complimentary tele-mentoring series on the optimal use of bispecific antibodies as cancer immunotherapies.

VIEW RECORDED SESSIONS
OncoLens Resources
All Resources

Blog

Case Studies

Education

CME

News and Events
About
OncoLens provides a first of its kind
multidisciplinary care platform.

More than 10% of all cancer centers and 50% of top pharma in the United States count on OncoLens to help improve outcomes through coordinated patient data, in-depth analysis, and actionable clinical decision support.

5,000,000+

Oncology patients under care within the network

85-90%

Accuracy in AI-driven Patient ID from unstructured data

278,000+

Multidisciplinary case discussions
About OncoLens
About Us

Meet Our Leadership Team

Awards

Meet Our Board of Directors
Contact Us

Careers

Schedule a Demo
Contact Us
Schedule Demo

Patient with Stage IB NSCLC, an Oncocyte DetermaRx High-Risk Result and an EGFR Exon 19 Deletion

Date Recorded:

February 1, 2021
Recording Length:

22:04
Topics:

EGFR, Exon 19 Deletion, lung cancer, NSCLC

Latest

Mar 31, 2025 | Case Studies

Oncology-Focused AI/LLM To Find the Right Patients for Your Clinical Trials

Mar 1, 2025 | Case Studies

OncoLens Analytics Enables a 350% Increase in Genetic Testing at Community Cancer Center

Feb 13, 2025 | Case Studies

Results of a Quality Improvement Program To Increase Complete Lung Cancer Biomarker Testing Rates

Nov 6, 2024 | Blog

The Lung-MAP (NCTID:03851445) Trial: Early Patient Tracking for Improved Accruals